Parikh Anand Kiran 4
4 · Faeth Therapeutics, Inc. · Filed Jul 23, 2026
Research Summary
AI-generated summary of this filing
Faeth (FTH) President & CEO Anand Parikh Receives Performance Option
What Happened Anand Kiran Parikh, President, CEO and Director of Faeth Therapeutics, was granted a performance-based stock option covering 398,018 shares on July 21, 2026. The award shows an acquisition price of $0.00 (derivative grant), so no cash was paid. The option only becomes exercisable if specified performance and service conditions are met.
Key Details
- Transaction date: July 21, 2026; Form 4 filed July 23, 2026 (appears timely under Form 4 rules).
- Grant: 398,018-share performance-based option; reported acquisition price $0.00; reported value $0 at grant.
- Shares owned after transaction: Not disclosed in the provided filing.
- Footnote F1 (performance vesting): Option vests only after the later of (a) any 30-consecutive-calendar-day average closing price ≥ $70.00 and (b) the first anniversary of grant; if the $70 hurdle is not met by the fourth anniversary, the option is forfeited. Continued service is required for vesting.
- Footnote F2 (change in control): If a Change in Control occurs before the performance period ends and the per-share consideration is ≥ $70 (subject to adjustment), the hurdle is deemed met and the option vests in full immediately prior to the transaction, subject to continued service; otherwise it is forfeited.
Context This filing reports a compensation grant (derivative award), not a market purchase or sale. Performance-based options like this are common executive compensation tied to a specific stock-price target; they do not indicate an immediate cash outlay or an insider sale.
Insider Transaction Report
- Award
Performance-Based Stock Option (right to buy)
[F1][F2]2026-07-21+398,018→ 398,018 totalExercise: $28.37Exp: 2036-07-20→ Common Stock (398,018 underlying)
Footnotes (2)
- [F1]Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the "Stock Price Hurdle") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the "Performance Period"), the option will be forfeited in its entirety.
- [F2]In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety.